Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17055
Title: Personalized chemosensitivity assays for mesothelioma- is it worth the effort?
Authors: John, Thomas;Chia, Puey Ling
Affiliation: Medical Oncology, Olivia Newton John Cancer Research Institute
Medical Oncology, University of Melbourne, Olivia Newton John Cancer Research Institute.
Issue Date: 19-Jan-2018
EDate: 2018
Citation: Clinical cancer research : an official journal of the American Association for Cancer Research 2018; online first: 19 January
Abstract: Cell-lines formed from an individual's tumor can be used to predict response to specific therapies and determine genomic predictors. For mesothelioma, where chemotherapy remains the backbone of current therapeutic paradigms, such assays could be used to treat patients with the most effective agents specific to their "chemical profile".
URI: http://ahro.austin.org.au/austinjspui/handle/1/17055
DOI: 10.1158/1078-0432.CCR-17-3493
PubMed URL: 29351918
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29351918
ISSN: 1078-0432
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.